Table 2.
Clinical characteristics of endometrial cancer patients with and without adenomyosis.
| Study | Total of Patients n |
Adenomyosis n (%) |
Age, [Years] Mean ± SD or Range) |
BMI Mean ± SD |
Premenopausal n (%) |
Post-Menopausal n (%) |
CA125 ± 35 IU/L n (%) |
Nulliparity | Multiparity | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2004 Koshiyama | 116 | Yes | 29 (25) | 54.2 ± 6.6 | - | 13 (45) | 16 (55) | - | - | - |
| No | 87 (75) | 57.7 ± 10.4 | - | 20 (23) | 67 (77) | - | - | - | ||
| 2014 Matsuo | 571 | Yes | 271 (47.4) | 52.7 ± 9.6 | 35.8 ± 9.1 | - | - | 59 (24.8) | 60 (23.3) | 197 (76.7) |
| No | 300 (52.5) | 52.7 ± 10.7 | 35.5 ± 10.7 | - | - | 82 (30) | 98 (34.4) | 187 (65.6) | ||
| 2017 Erkilinc | 1242 | Yes | 80 (20) | 56 ± 8.9 | 32.4 ± 7.0 | - | - | - | - | - |
| No | 320 (80) | 59 ± 24.8 | 32.9 ± 5.1 | - | - | - | - | - | ||
| 2017 Mao | 127 | Yes | 24 (18.8) | 50.7 (31–71) | - | - | 9 (37.5) | 3 (1.3) | 0 | - |
| No | 103 (81.1) | 51.5 (31–72) | - | - | 73 (70.9) | 8 (7.8) | 4 (3.9) | - | ||
| 2017 Zhang | 1584 | Yes | 150 (9.4) | 53 | 27 | 69 (46) | 81 (54) | - | - | - |
| No | 1434 (90.5) | 55 | 26.6 | 504 (35.1) | 930 (64.8) | - | - | - | ||
| 2018 Boonlak | 350 | Yes | 132 (37.7) | 59 (36–80) | 25.4 ± 4.8 | - | - | - | 33 (25) | 99 (75) |
| No | 218 (62.2) | 58 (31–84) | 25.2 ± 4.2 | - | - | - | 56 (25.7) | 162 (74) | ||
| 2019 Zouzoulas | 229 | Yes | 64 (27.9) | 63.2 ± 9.4 | - | - | 56 (87.5) | 10 (19.6) | - | - |
| No | 165 (72) | 64.2 ± 12.3 | - | - | 138 (83.6) | 31 (22.6) | - | - | ||
| 2020 Jonhatty | 1399 | Yes | 572 (40.8) | 60.8 (31.9–80) | - | - | - | - | 65 (11.4) | 507 (88.6) |
| No | 827 (59.1) | 61.6 (26.4–80) | - | - | - | - | 182 (22.0) | 645 (78) |
SD: standard deviation; BMI: body mass index; CA125: cancer antigen 125.